Липосомы – метаболически активные транспортные системы лекарственных средств: визуализация и фармакокинетика. Часть 2 (обзор)

Введение. Во второй части обзора рассмотрены вопросы визуализации, фармакокинетики и биораспределения липосом.

Текст. Существует широкий спектр методов визуализации, доступных для оценки морфологии липосом и их качества, каждый из которых имеет свои преимущества и недостатки: световая микроскопия, ESEM, TEM, AFM и пр. В целом выбор метода зависит от того, какие морфологические характеристики и степень детализации требуются. В процессе подготовки проб липосом важно понимать особенности образцов и метода визуализации. Адекватно проведенные исследования по фармакокинетике и биораспределению также могут расцениваться как инструмент визуализации липосом. Фармакокинетика липосомальных форм определяется множеством факторов, таких как природа ЛС, дозировка, липидный состав, размер липосом, заряд, покрытие липосом вспомогательными веществами и способ введения. Кроме того, взаимодействие липосомальных форм с иммунной системой, ретикулоэндотелиальной системой и компонентами крови играет важную роль в их абсорбции, распределении и выведении из организма.

Заключение. Лучшее понимание абсорбции, биораспределения, метаболизма и выведения липосомальных форм необходимо для разработки современных лекарственных средств.

1. Осочук С. С., Коцур Ю. М., Пожарицкая О. Н., Флисюк Е. В., Смехова И. Е., Малков С. Д., Зарифи К. О., Титович И. А., Красова Е. К., Шиков А. Н. Липосомы – метаболически активные транспортные системы лекарственных средств: классификация, составные компоненты, способы изготовления и стабилизации. Часть 1. Разработка и регистрация лекарственных средств. 2024;4. DOI: 10.33380/2305-2066-2024-13-4-1867.

2. Bibi S., Kaur R., Henriksen-Lacey M., McNeil S. E., Wilkhu J., Lattmann E., Christensen D., Mohammed A. R., Perrie Y. Microscopy imaging of liposomes: from coverslips to environmental SEM. International Journal of Pharmaceutics. 2011;417(1–2):138–150. DOI: 10.1016/j.ijpharm.2010.12.021.

3. Nallamothu R., Wood G. C., Pattillo C. B., Scott R. C., Kiani M. F., Moore B. M., Thoma L. A. A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation. AAPS PharmSciTech. 2006;7(2):E32. DOI: 10.1208/pt070232.

4. Bouvrais H., Pott T., Bagatolli L. A., Ipsen J. H., Méléard P. Impact of membrane-anchored fluorescent probes on the mechanical properties of lipid bilayers. Biochimica et Biophysica Acta (BBA) – Biomembranes. 2010;1798(7):1333–1337. DOI: 10.1016/j.bbamem.2010.03.026.

5. Klymchenko A. S., Oncul S., Didier P., Schaub E., Bagatolli L., Duportail G., Mély Y. Visualization of lipid domains in giant unilamellar vesicles using an environment-sensitive membrane probe based on 3-hydroxyflavone. Biochimica et Biophysica Acta (BBA) – Biomembranes. 2009;1788(2):495–499. DOI: 10.1016/j.bbamem.2008.10.019.

6. Mertins O., Dimova R. Insights on the interactions of chitosan with phospholipid vesicles. Part II: membrane stiffening and pore formation. Langmuir. 2013;29(47):14552–14559. DOI: 10.1021/la4032199.

7. Ruozi B., Belletti D., Tombesi A., Tosi G., Bondioli L., Forni F., Vandelli M. A. AFM, ESEM, TEM, and CLSM in liposomal characterization: a comparative study. International Journal of Nanomedicine. 2011;6:557–563. DOI: 10.2147/IJN.S14615.

8. Karakas C. Y., Ustundag C. B., Sahin A., Karadag A. Co-axial electrospinning of liposomal propolis loaded gelatin-zein fibers as a potential wound healing material. Journal of Applied Polymer Science. 2023;140(46):e54683. DOI: 10.1002/app.54683.

9. Johnston M. J. W., Edwards K., Karlsson G., Cullis P. R. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. Journal of Liposome Research. 2008;18(2):145–157. DOI: 10.1080/08982100802129372.

10. Zhigaltsev I. V., Maurer N., Akhong Q.-F., Leone R., Leng E., Wang J., Semple S. C., Cullis P. R. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. Journal of Controlled Release. 2005;104(1):103–111. DOI: 10.1016/j.jconrel.2005.01.010.

11. Damari S. P., Shamrakov D., Varenik M., Koren E., Nativ-Roth E., Barenholz Y., Regev O. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes. International Journal of Pharmaceutics. 2018;547(1–2):648–655. DOI: 10.1016/j.ijpharm.2018.06.037.

12. Kuntsche J., Horst J. C., Bunjes H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. International Journal of Pharmaceutics. 2011;417(1–2):120–137. DOI: 10.1016/j.ijpharm.2011.02.001.

13. Resnik N., Romih R., Kreft M. E., Hudoklin S. Freeze-fracture electron microscopy for extracellular vesicle analysis. Journal of Visualized Experiments. 2022;187:e63550. DOI: 10.3791/63550.

14. Perrie Y., Ali H., Kirby D. J., Mohammed A. U. R., McNeil S. E., Vangala A. Environmental scanning electron microscope imaging of vesicle systems. Methods in Molecular Biology. 2017;1522:131–143. DOI: 10.1007/978-1-4939-6591-5_11.

15. Takahashi N., Higashi K., Ueda K., Yamamoto K., Moribe K. Determination of nonspherical morphology of doxorubicin-loaded liposomes by atomic force microscopy. Journal of Pharmaceutical Sciences. 2018;107(2):717–726. DOI: 10.1016/j.xphs.2017.10.009.

16. Ruozi B., Tosi G., Leo E., Vandelli M. A. Application of atomic force microscopy to characterize liposomes as drug and gene carriers. Talanta. 2007;73(1):12–22. DOI: 10.1016/j.talanta.2007.03.031.

17. Ле-Дейген И. М., Скуредина А. А., Кудряшова Е. В. Экспериментальные методы исследования механизма взаимодействия липидных мембран с низкомолекулярными лекарствами. Биоорганическая химия. 2020;46(4):340–359. DOI: 10.31857/S013234232004017X.

18. Швецов И. С. Влияние pН среды гидратируемого раствора на морфологические характеристики лецитиновых липосом. Современная наука: актуальные проблемы теории и практики. Серия: Естественные и технические науки. 2021;(5):236–240. DOI: 10.37882/2223-2966.2021.05.36.

19. Бурдаев Н. И., Николаева Л. Л., Косенко В. В., Шпрах З. С., Бунятян Н. Д. Липосомы как носители лекарственных средств: классификация, методы получения и применение. Ведомости Научного центра экспертизы средств медицинского применения. Регуляторные исследования и экспертиза лекарственных средств. 2023;13(2–1):316–332. DOI: 10.30895/1991-2919-2023-508.

20. Bagatolli L. A. Membranes and Fluorescence Microscopy. Reviews in Fluorescence. 2009;33–51. DOI: 10.1007/978-0-387-88722-7_2.

21. Murphy D. B., Davidson M. W. Polarization Microscopy. In: Fundamentals of Light Microscopy and Electronic Imaging. New Jersey: John Wiley & Sons, Inc.; 2012. P. 153–171. DOI: 10.1002/9781118382905.

22. Murphy D. B., Davidson M. W. Fluorescence Microscopy. In: Fundamentals of Light Microscopy and Electronic Imaging. New Jersey: John Wiley & Sons, Inc.; 2012. P. 199–231. DOI: 10.1002/9781118382905.ch11.

23. Murphy D. B., Davidson M. W. Confocal Laser Scanning Microscopy. In: Fundamentals of Light Microscopy and Electronic Imaging. New Jersey: John Wiley & Sons, Inc.; 2012. P. 265–305. DOI: 10.1002/9781118382905.ch13.

24. Henry C. R. Morphology of supported nanoparticles. Progress in Surface Science. 2005;80(3–4):92–116. DOI: 10.1016/j.progsurf.2005.09.004.

25. Robson A.-L., Dastoor P. C., Flynn J., Palmer W., Martin A., Smith D. W., Woldu A., Hua S. Advantages and limitations of current imaging techniques for characterizing liposome morphology. Frontiers in Pharmacology. 2018;9:328115. DOI: 10.3389/fphar.2018.00080.

26. Adler K., Schiemann J. Characterization of liposomes by scanning electron microscopy and the freeze-fracture technique. Micron and Microscopica Acta. 1985;16(2):109–113. DOI: 10.1016/0739-6260(85)90039-5.

27. Baxa U. Imaging of liposomes by transmission electron microscopy. Methods in Molecular Biology. 2018;1682:73–88. DOI: 10.1007/978-1-4939-7352-1_8.

28. Anabousi S., Laue M., Lehr C.-M., Bakowsky U., Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. European Journal of Pharmaceutics and Biopharmaceutics. 2005;60(2):295–303. DOI: 10.1016/j.ejpb.2004.12.009.

29. Dürr V., Wohlfart S., Eisenzapf T., Mier W., Fricker G., Uhl P. Oral Delivery of mRNA by Liposomes Functionalized with Cell-Penetrating Peptides. Applied Nano. 2023;4(4):293–308. DOI: 10.3390/applnano4040017.

30. Mohammed A. R., Weston N., Coombes A. G. A., Fitzgerald M., Perrie Y. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. International Journal of Pharmaceutics. 2004;285(1–2):23–34. DOI: 10.1016/j.ijpharm.2004.07.010.

31. Sitterberg J., Özcetin A., Ehrhardt C., Bakowsky U. Utilising atomic force microscopy for the characterisation of nanoscale drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics. 2010;74(1):2–13. DOI: 10.1016/j.ejpb.2009.09.005.

32. Engelhardt K., Preis E., Bakowsky U. Visualization and characterization of liposomes by atomic force microscopy. In: Liposomes. Methods and Protocols. New York: Springer Nature; 2023. P. 253–263. DOI: 10.1007/978-1-0716-2954-3_23.

33. Sheikholeslami B., Lam N. W., Dua K., Haghi M. Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sciences. 2022;300:120574. DOI: 10.1016/j.lfs.2022.120574.

34. Paramshetti S., Angolkar M., Talath S., Osmani R. A. M., Spandana A., Al Fatease A., Hani U., Ramesh K. V. R. N. S., Singh E. Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions. Life Sciences. 2024;346:122616. DOI: 10.1016/j.lfs.2024.122616.

35. Su J., Lu W., Guo Y., Liu Z., Wang X., Yan H., Zhang R. X. Depot unilamellar liposomes to sustain transscleral drug Co-delivery for ophthalmic infection therapy. Journal of Drug Delivery Science and Technology. 2023;86:104629. DOI: 10.1016/j.jddst.2023.104629.

36. Tian H., Chang M., Lyu Y., Dong N., Yu N., Yin T., Zhang Y., He H., Gou J., Tang X. Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving in-situ stability. Expert Opinion on Drug Delivery. 2024;21(1):169–185. DOI: 10.1080/17425247.2024.2305110.

37. Peng J., Wang Q., Sun R., Zhang K., Chen Y., Gong Z. Phospholipids of inhaled liposomes determine the in vivo fate and therapeutic effects of salvianolic acid B on idiopathic pulmonary fibrosis. Journal of Controlled Release. 2024;371:1–15. DOI: 10.1016/j.jconrel.2024.05.026.

38. Duong V.-A., Nguyen T.-T.-L., Maeng H.-J. Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics. 2023;15(1):207. DOI: 10.3390/pharmaceutics15010207.

39. Liu J., Zheng A., Peng B., Xu Y., Zhang N. Size-dependent absorption through stratum corneum by drug-loaded liposomes. Pharmaceutical Research. 2021;38:1429–1437. DOI: 10.1007/s11095-021-03079-9.

40. Li H., Tang Q., Wang Y., Li M., Wang Y., Zhu H., Geng F., Wu D., Peng L., Zhao G., Zou L., Shi S. Injectable thermosensitive lipo-hydrogels loaded with ropivacaine for prolonging local anesthesia. International Journal of Pharmaceutics. 2022;611:121291. DOI: 10.1016/j.ijpharm.2021.121291.

41. Pokharkar V., Patil-Gadhe A., Palla P. Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study. Biomedicine & Pharmacotherapy. 2017;94:150–164. DOI: 10.1016/j.biopha.2017.07.067.

42. Xiang Y., Long Y., Yang Q., Zheng C., Cui M., Ci Z., Lv X., Li N., Zhang R. Pharmacokinetics, pharmacodynamics and toxicity of Baicalin liposome on cerebral ischemia reperfusion injury rats via intranasal administration. Brain Research. 2020;1726:146503. DOI: 10.1016/j.brainres.2019.146503.

43. Wei H., Liu T., Jiang N., Zhou K., Yang K., Ning W., Yu Y. A novel delivery system of cyclovirobuxine D for brain targeting: Angiopep-conjugated polysorbate 80-coated liposomes via intranasal administration. Journal of Biomedical Nanotechnology. 2018;14(7):1252–1262. DOI: 10.1166/jbn.2018.2581.

44. Liu Q., Guan J., Qin L., Zhang X., Mao S. Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discovery Today. 2020;25(1):150–159. DOI: 10.1016/j.drudis.2019.09.023.

45. Ferguson L. T., Ma X., Myerson J. W., Wu J., Glassman P. M., Zamora M. E., Hood E. D., Zaleski M., Shen M., Essien E.-O., Shuvaev V. V., Brenner J. S. Mechanisms by which liposomes improve inhaled drug delivery for alveolar diseases. Advanced NanoBiomed Research. 2023;3(3):2200106. DOI: 10.1002/anbr.202200106.

46. Lai S., Wei Y., Wu Q., Zhou K., Liu T., Zhang Y., Jiang N., Xiao W., Chen J., Liu Q., Yu Y. Liposomes for effective drug delivery to the ocular posterior chamber. Journal of Nanobiotechnology. 2019;17:64. DOI: 10.1186/s12951-019-0498-7.

47. Zhang G., Li X., Huang C., Jiang Y., Su J., Hu Y. Preparation of the Levo-Tetrahydropalmatine Liposome Gel and Its Transdermal Study. International Journal of Nanomedicine. 2023;18:4617–4632. DOI: 10.2147/IJN.S422305.

48. Chabru A. S., Salve P. S., Ghumare G. D., Dhamak R. S., Tiwari D. R., Waghmare D. S. Comparative pharmacokinetic studies of transferosomes loaded gel and pressure sensitive adhesive based patch formulation for transdermal delivery of benztropine mesylate. Journal of Drug Delivery Science and Technology. 2024;92:105287. DOI: 10.1016/j.jddst.2023.105287.

49. Yu A.-M., Tu M.-J. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. Pharmacology & Therapeutics. 2022;230:107967. DOI: 10.1016/j.pharmthera.2021.107967.

50. Uhl P., Helm F., Hofhaus G., Brings S., Kaufman C., Leotta K., Urban S., Haberkorn U., Mier W., Fricker G. A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. European Journal of Pharmaceutics and Biopharmaceutics. 2016;103:159–166. DOI: 10.1016/j.ejpb.2016.03.031.

51. Leal J., Dong T., Taylor A., Siegrist E., Gao F., Smyth H. D. C., Ghosh D. Mucus-penetrating phage-displayed peptides for improved transport across a mucus-like model. International Journal of Pharmaceutics. 2018;553(1–2):57–64. DOI: 10.1016/j.ijpharm.2018.09.055.

52. Карлина М. В., Косман В. М., Пожарицкая О. Н., Шиков А. Н., Макарова М. Н., Макаров В. Г., Балабаньян В. Ю. Экспериментальное исследование фармакокинетики рифабутина в липосомальной форме. Фармакокинетика и фармакодинамика. 2013;(2):37–41.

53. El-Helaly S. N., Abd Elbary A., Kassem M. A., El-Nabarawi M. A. Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. Drug Delivery. 2017;24(1):692–700. DOI: 10.1080/10717544.2017.1309476.

54. Rip J., Chen L., Hartman R., van den Heuvel A., Reijerkerk A., van Kregten J., van der Boom B., Appeldoorn C., de Boer M., Maussang D., de Lange E. C. M., Gaillard P. J. Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood–brain barrier in rats. Journal of Drug Targeting. 2014;22(5):460–467. DOI: 10.3109/1061186X.2014.888070.

55. Dadpour S., Mehrabian A., Arabsalmani M., Mirhadi E., Askarizadeh A., Mashreghi M., Jaafari M. R. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity. IET Nanobiotechnology. 2022;16(7–8):259–272. DOI: 10.1049/nbt2.12094.

56. Guo P., Liu D., Subramanyam K., Wang B., Yang J., Huang J., Auguste D. T., Moses M. A. Nanoparticle elasticity directs tumor uptake. Nature Communications. 2018;9(1):130. DOI: 10.1038/s41467-017-02588-9.

57. Krasnici S., Werner A., Eichhorn M. E., Schmitt-Sody M., Pahernik S. A., Sauer B., Schulze B., Teifel M., Michaelis U., Naujoks K., Dellian M. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. International Journal of Cancer. 2003;105(4):561–567. DOI: 10.1002/ijc.11108.

58. Wang H.-X., Zuo Z.-Q., Du J.-Z., Wang Y.-C., Sun R., Cao Z.-T., Ye X.-D., Wang J.-L., Leong K. W., Wang J. Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines. Nano Today. 2016;11(2):133–144. DOI: 10.1016/j.nantod.2016.04.008.

59. Large D. E., Soucy J. R., Hebert J., Auguste D. T. Advances in receptor-mediated, tumor-targeted drug delivery. Advanced Therapeutics. 2019;2(1):1800091. DOI: 10.1002/adtp.201800091.

60. Ishida T., Harashima H., Kiwada H. Liposome clearance. Bioscience Reports. 2002;22(2):197–224. DOI: 10.1023/a:1020134521778.

61. Ait-Oudhia S., Mager D. E., Straubinger R. M. Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics. 2014;6(1):137–174. DOI: 10.3390/pharmaceutics6010137.

62. Akhter M. H., Ahmad I., Alshahrani M. Y., Al-Harbi A. I., Khalilullah H., Afzal O., Altamimi A. S. A., Najib Ullah S. N. M., Ojha A., Karim S. Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System. Gels. 2022;8(2):82. DOI: 10.3390/gels8020082.

63. Tavakoli S., Peynshaert K., Lajunen T., Devoldere J., del Amo E. M., Ruponen M., De Smedt S. C., Remaut K., Urtti A. Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface. Journal of Controlled Release. 2020;328:952–961. DOI: 10.1016/j.jconrel.2020.10.028.

64. Dhaliwal H. K., Fan Y., Kim J., Amiji M. M. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Molecular Pharmaceutics. 2020; 17(6):1996–2005. DOI: 10.1021/acs.molpharmaceut.0c00170.

65. Carter P., Narasimhan B., Wang Q. Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases. International Journal of Pharmaceutics. 2019;555:49–62. DOI: 10.1016/j.ijpharm.2018.11.032.

66. Matharoo N., Mohd H., Michniak-Kohn B. Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2024;16(1):e1918. DOI: 10.1002/wnan.1918.

67. Chen T., He B., Tao J., He Y., Deng H., Wang X., Zheng Y. Application of Förster Resonance Energy Transfer (FRET) technique to elucidate intracellular and In Vivo biofate of nanomedicines. Advanced Drug Delivery Reviews. 2019;143:177–205. DOI: 10.1016/j.addr.2019.04.009.

68. Peng T., Xu W., Li Q., Ding Y., Huang Y. Pharmaceutical liposomal delivery—specific considerations of innovation and challenges. Biomaterials Science. 2023;11(1):62–75. DOI: 10.1039/D2BM01252A.

69. Allen T. M., Cullis P. R. Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews. 2013;65(1):36–48. DOI: 10.1016/j.addr.2012.09.037.

70. Hume D. A. The mononuclear phagocyte system. Current Opinion in Immunology. 2006;18(1):49–53. DOI: 10.1016/j.coi.2005.11.008.

71. Betker J. L., Jones D., Childs C. R., Helm K. M., Terrell K., Nagel M. A., Anchordoquy T. J. Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery. Journal of Controlled Release. 2018;286:85–93. DOI: 10.1016/j.jconrel.2018.07.031.

72. Giambelluca M., Markova E., Louet C., Steinkjer B., Sundset R., Škalko-Basnet N., Hak S. Liposomes-Human phagocytes interplay in whole blood: effect of liposome design. Nanomedicine: Nanotechnology, Biology and Medicine. 2023;54:102712. DOI: 10.1016/j.nano.2023.102712.

73. Mochalova E. N., Egorova E. A., Komarova K. S., Shipunova V. O., Khabibullina N. F., Nikitin P. I., Nikitin M. P. Comparative study of nanoparticle blood circulation after forced clearance of own erythrocytes (mononuclear phagocyte system-cytoblockade) or administration of cytotoxic doxorubicinor clodronate-loaded liposomes. International Journal of Molecular Sciences. 2023;24(13):10623. DOI: 10.3390/ijms241310623.

74. Large D. E., Abdelmessih R. G., Fink E. A., Auguste D. T. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Advanced Drug Delivery Reviews. 2021;176:113851. DOI: 10.1016/j.addr.2021.113851.

75. Scherphof G. L., Kamps J. A. A. M. The role of hepatocytes in the clearance of liposomes from the blood circulation. Progress in Lipid Research. 2001;40(3):149–166. DOI: 10.1016/s0163-7827(00)00020-5.

76. Shi D., Beasock D., Fessler A., Szebeni J., Ljubimova J. Y., Afonin K. A., Dobrovolskaia M. A. To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Advanced Drug Delivery Reviews. 2022;180:114079. DOI: 10.1016/j.addr.2021.114079.

77. Xu G., Yang D., He C., Zhong L., Zhu J., Shu Q., Ding H., Xin W., Tong Y., Zhu X., Fang L. Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 2023;92(3):181–192. DOI: 10.1007/s00280-023-04559-y.

78. Yamazoe E., Fang J.-Y., Tahara K. Oral mucus-penetrating PEGylated liposomes to improve drug absorption: Differences in the interaction mechanisms of a mucoadhesive liposome. International Journal of Pharmaceutics. 2021;593:120148. DOI: 10.1016/j.ijpharm.2020.120148.

79. Haroon H. B., Hunter A. C., Farhangrazi Z. S., Moghimi S. M. A brief history of long circulating nanoparticles. Advanced Drug Delivery Reviews. 2022;188:114396. DOI: 10.1016/j.addr.2022.114396.